Cancer remains a leading cause of death worldwide, yet millions lack access to reliable, affordable treatments.

📈Why it's important: By 2040, new annual cancer cases are projected to surge to almost 30 million with 15.3 million deaths per year.

• The economic toll is also staggering, with global oncology treatment costs expected to reach $400 billion by 2027.

Here's the deal: Innovative new cancer treatments, such as biologics, are crucial to improving outcomes and reaching more patients globally.

● Biologics, which are medical products created from a living organism, are transforming the oncology space as they can target diseases more precisely.

● They can be used to treat a range of diseases, from cancer to arthritis.

Okay, but: Bringing these groundbreaking medicines to market is very complex and can take years, delaying patient access.

What you need to know: BeiGene, a global oncology company, is helping improve access, equity and affordability with a unique science-first model designed to create innovative therapies that are more affordable and accessible more quickly.

🔬How it's done: The company's model consists of running global clinical trials in-house, reducing costs and improving the speed of drug development by up to 30% while ensuring the highest quality production.

In just over a decade, BeiGene's model has:

● Generated a robust oncology pipeline addressing 80% of the world's cancers by incidence, fueled by one of the industry's largest and most productive research teams.

● Conducted more than 140 clinical trials among more than 20,000 patients around the world.

● Received regulatory approvals in more than 70 markets across three internally developed medicines.

🧪Even better: BeiGene is taking its capabilities further with its new U.S. flagship facility at the Princeton West Innovation Campus in Hopewell, New Jersey.

● The company is investing $800 million in this center and is expected to employ hundreds of workers in high-paying jobs by the end of 2025.

● Plus, plus, plus: The facility features eco-friendly design and construction practices to reduce its environmental impact.

The deets: The 400,000-square-foot space houses a state-of-the-art commercial-stage biologics manufacturing facility and a clinical research and development center.

● The flagship expands BeiGene's production of complex biologics, like PD-1 inhibitor TEVIMBRAⓇ (tislelizumab-jsgr), which has treated over 1 million patients worldwide.

"The company has experienced rapid global growth, and the addition of these manufacturing and R&D capabilities in the U.S. supports our broader expansion strategy to ensure we get our innovative medicines to far more patients around the world," said John V. Oyler, co-founder, chairman and CEO of BeiGene.

🤝Worth a mention: BeiGene initially started with a gathering of a few employees in Valley Forge before opening an office in nearby Philadelphia. Today, the company is committed to making a significant investment in New Jersey — beyond construction and staffing — to ensure it's a responsible and positive force in the community.

● The company is actively working with local businesses, government, community groups, academic institutions, hospitals and cancer-focused nonprofits to expand training, STEM education and patient support.

● An example: Its partnership with Crossroads4Hope, a nonprofit committed to transforming the cancer experience across New Jersey, allowed the organization to expand the reach of its psychosocial support programs to more vulnerable patients and communities.

The takeaway: As a trailblazer in global oncology drug development, BeiGene's unique model and new U.S. facility will play a vital role in accelerating the production of potentially life-changing medicines for more cancer patients worldwide.

Learn more.